Hip FracturesNCT06935071
Endoprosthetic Replacement for Pathological Fractures of the Hip: A 35-year Update
An observational study of Hip Fractures and Hip Fracture Pathologic, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
Trial summary
This study will be based on a retrospective review of patients who received endoprosthetic reconstruction for pathologic fracture of the proximal femur. The objectives would be two-fold: (1) to compare rates ofambulation, pain, and survival to the historic cohort and (2) to identify predictors of ambulation in the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hip Fractures, Hip Fracture Pathologic, Pathological Fracture
- What is being tested?
- Data Collection and Analysis
- How many people
- 300 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Aug 2016to 4 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: For this retrospective data review, the study team will query the orthopaedic caisis database and IDB to obtain a list of all participants who have received endoprosthetic reconstruction for pathologic fracture of the proximal femur.
Who may be able to join
- Participants have received endoprosthetic reconstruction for pathologic fracture of the proximal femur
Who cannot join
- Participants with fractures greater than 3mm from the lesser trochanter
- Participants without histopathologic confirmation of tumor
Trial locations and contacts
1 site in 1 country.
United States1 site
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
About this study
This study will be based on a retrospective review of patients who received endoprosthetic reconstruction for pathologic fracture of the proximal femur. The objectives would be two-fold: (1) to compare rates ofambulation, pain, and survival to the historic cohort and (2) to identify predictors of ambulation in the current population.
- Conditions
- Hip Fractures, Hip Fracture Pathologic, Pathological Fracture, Pathological Fracture of Hip
- Being tested
- Data Collection and Analysis
- Keywords
- hip fractures, pathological hip fractures, hip fracture parthologic, pathological fracture of hip, 16-1122, Memorial Sloan Kettering Cancer Center
- Medical subject headings
- Hip Fractures, Fractures, Spontaneous
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Data Collection and AnalysisOther
Patient data will be analyzed to ensure that all data fields are available and that suitable sample size is available to answer the research objectives. The rate of ambulation at discharge, ambulation at 3 month follow up (if available), time to death, and pain score between the historic cohort with a current cohort of patients will be compared.
| Study group | Role | What they receive |
|---|---|---|
| Participants who received endoprosthetic reconstruction | Participants have received endoprosthetic reconstruction for pathologic fracture of the proximal femur. Receives: Other: Data Collection and Analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of rates of ambulation, pain, and survival to the historic cohort
This study will be based on a retrospective review of patients who received endoprosthetic reconstruction for pathologic fracture of the proximal femur.
Measured: up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2025
- Study start4 Aug 2016
- Primary completion4 Aug 2027 (estimated)
- Study completion4 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip FracturesStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- John Healey, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06935071
- Sponsor's protocol ID
- 16-1122
- Status last verified
- Sep 2026
- First submitted
- 11 Apr 2025
- Last updated
- 4 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: • Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Endoprosthetic Replacement for Pathological Fractures of the Hip: A 35-year Update
- ClinicalTrials.gov ID
- NCT06935071
- Acronym / sponsor ID
- 16-1122
- Conditions
- Hip Fractures, Hip Fracture Pathologic, Pathological Fracture, Pathological Fracture of Hip
- Keywords
- hip fractures, pathological hip fractures, hip fracture parthologic, pathological fracture of hip, 16-1122, Memorial Sloan Kettering Cancer Center
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 300 participants (actual)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Study start
- 4 Aug 2016 (actual)
- Primary completion
- 4 Aug 2027 (estimated)
- Study completion
- 4 Aug 2027 (estimated)
- First posted
- 18 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will be based on a retrospective review of patients who received endoprosthetic reconstruction for pathologic fracture of the proximal femur. The objectives would be two-fold: (1) to compare rates ofambulation, pain, and survival to the historic cohort and (2) to identify predictors of ambulation in the current population.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants who received endoprosthetic reconstruction | – | Other: Data Collection and AnalysisParticipants have received endoprosthetic reconstruction for pathologic fracture of the proximal femur. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- For this retrospective data review, the study team will query the orthopaedic caisis database and IDB to obtain a list of all participants who have received endoprosthetic reconstruction for pathologic fracture of the proximal femur.
Key inclusion criteria (1 listed)
- Participants have received endoprosthetic reconstruction for pathologic fracture of the proximal femur
Key exclusion criteria (2 listed)
- Participants with fractures greater than 3mm from the lesser trochanter
- Participants without histopathologic confirmation of tumor
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Data Collection and AnalysisPatient data will be analyzed to ensure that all data fields are available and that suitable sample size is available to answer the research objectives. The rate of ambulation at discharge, ambulation at 3 month follow up (if available), time to death, and pain score between the historic cohort with a current cohort of patients will be compared. | Other | Participants who received endoprosthetic reconstruction |
Primary outcome
Comparison of rates of ambulation, pain, and survival to the historic cohort
Time frame: up to 10 years
This study will be based on a retrospective review of patients who received endoprosthetic reconstruction for pathologic fracture of the proximal femur.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. • Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Related trials for Hip Fractures
Not yet recruitingPhase 4
Effect of Ondansetron on the Incidence of Spinal Anaesthesia-Induced Hypotension in Elderly Patients Undergoing Fracture Hip Surgery
Spinal Anaesthesia Induced Hypotension
Not yet recruiting
Lumbar Erector Spinae Plane Block Versus PENG Block for Hip Fracture Surgery
Femur Neck Fracture, Hip Fractures
Active, not recruiting
Lumbar-Sacral Plexus Block vs Fascia Iliaca Block Plus Low-Dose Spinal Anesthesia for Femoral Neck Fracture Surgery
Femoral Neck Fractures, Nerve Block
RecruitingObservational study
Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures
Fracture; Pelvic, Insufficiency Fractures
Not yet recruiting
A Decision Support Tool for Common Surgical Fixations of Hip Fractures
Hip Fracture Surgeries, High Risk Population of Hip Fractures
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John Healey, MD principal investigator
Memorial Sloan Kettering Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Fractures and Hip Fracture Pathologic, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of rates of ambulation, pain, and survival to the historic cohort (time frame: up to 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.